| Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis NR Gandhi, P Nunn, K Dheda, HS Schaaf, M Zignol, D Van Soolingen, ... The Lancet 375 (9728), 1830-1843, 2010 | 1369 | 2010 |
| Global incidence of multidrug-resistant tuberculosis M Zignol, MS Hosseini, A Wright, CL Weezenbeek, P Nunn, CJ Watt, ... The Journal of infectious diseases 194 (4), 479-485, 2006 | 854 | 2006 |
| WHO consolidated guidelines on drug-resistant tuberculosis treatment N Cocco, G Gargioni, C Gilpin, L Gonzalez-Angulo, M Grzemska, ... World Health Organization, 2019 | 822 | 2019 |
| WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update D Falzon, E Jaramillo, HJ Schünemann, M Arentz, M Bauer, J Bayona, ... European Respiratory Journal 38 (3), 516-528, 2011 | 820 | 2011 |
| Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis N Ahmad, SD Ahuja, OW Akkerman, JWC Alffenaar, LF Anderson, ... The Lancet 392 (10150), 821-834, 2018 | 583 | 2018 |
| Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance A Wright, M Zignol, A Van Deun, D Falzon, SR Gerdes, K Feldman, ... The Lancet 373 (9678), 1861-1873, 2009 | 551 | 2009 |
| A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis G Lamichhane, M Zignol, NJ Blades, DE Geiman, A Dougherty, J Grosset, ... Proceedings of the National Academy of Sciences 100 (12), 7213-7218, 2003 | 446 | 2003 |
| Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues CJ Meehan, GA Goig, TA Kohl, L Verboven, A Dippenaar, M Ezewudo, ... NATURE reviews microbiology 17 (9), 533-545, 2019 | 399 | 2019 |
| Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010 M Zignol, W Gemert, D Falzon, C Sismanidis, P Glaziou, K Floyd, ... Bulletin of the world Health Organization 90, 111-119, 2012 | 389 | 2012 |
| Drug-resistant tuberculosis: time for visionary political leadership I Abubakar, M Zignol, D Falzon, M Raviglione, L Ditiu, S Masham, I Adetifa, ... The Lancet infectious diseases 13 (6), 529-539, 2013 | 374 | 2013 |
| A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis P Miotto, B Tessema, E Tagliani, L Chindelevitch, AM Starks, C Emerson, ... European Respiratory Journal 50 (6), 2017 | 370 | 2017 |
| Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF K Weyer, F Mirzayev, GB Migliori, W Van Gemert, L D'Ambrosio, M Zignol, ... European Respiratory Journal 42 (1), 252-271, 2013 | 369 | 2013 |
| Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs World Health Organization < bound method Organization. get_name_with_acronym of< Organization: World …, 2008 | 325 | 2008 |
| Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors A Skrahina, H Hurevich, A Zalutskaya, E Sahalchyk, A Astrauko, S Hoffner, ... Bulletin of the World Health Organization 91, 36-45, 2013 | 265 | 2013 |
| World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update F Mirzayev, K Viney, NN Linh, L Gonzalez-Angulo, M Gegia, E Jaramillo, ... European Respiratory Journal 57 (6), 2021 | 263 | 2021 |
| Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk A Skrahina, H Hurevich, A Zalutskaya, E Sahalchyk, A Astrauko, ... European Respiratory Journal 39 (6), 1425-1431, 2012 | 242 | 2012 |
| National tuberculosis prevalence surveys in Asia, 1990–2012: an overview of results and lessons learned I Onozaki, I Law, C Sismanidis, M Zignol, P Glaziou, K Floyd Tropical Medicine & International Health 20 (9), 1128-1145, 2015 | 216 | 2015 |
| Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project M Zignol, AS Dean, N Alikhanova, S Andres, AM Cabibbe, DM Cirillo, ... The Lancet infectious diseases 16 (10), 1185-1192, 2016 | 215 | 2016 |
| Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report S Borisov, E Danila, A Maryandyshev, M Dalcolmo, S Miliauskas, L Kuksa, ... European Respiratory Journal 54 (6), 2019 | 206 | 2019 |
| Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects EV Kurbatova, A Taylor, VM Gammino, J Bayona, M Becerra, M Danilovitz, ... Tuberculosis 92 (5), 397-403, 2012 | 197 | 2012 |
Mario RaviglioneProfessor of Global Health, University of Milan, ItalyEmail được xác minh tại unimi.it
